Pharmacological disruption of this axis using the extracellular domain of TMEM219 (ecto-TMEM219) provides temporally distinct benefits in preclinical diabetes models by initially enhancing beta-cell survival and preventing diabetes onset and promoting beta-cell expansion in the long-term (83). This evidence concerns the gene TMEM219 and diabetes mellitus.